Intuitive Surgical's Beat-and-Miss Quarter: Strong Earnings Overshadowed by US Slowdown and Unchanged Guidance

Intuitive Surgical beat Q2 expectations but stock tumbled 14% as unchanged guidance and US procedure slowdown raised concerns about growth sustainability.

Intuitive Surgical delivered better-than-expected second-quarter numbers on Thursday, yet the stock suffered its worst single-day decline in months on Friday, plunging more than 14% to €302.00 — a fresh 52-week low. The disconnect highlights a recurring theme on Wall Street: a strong rearview mirror means little when the road ahead looks bumpy.

Adjusted earnings per share came in at $2.80, comfortably above the analyst consensus of $2.51 to $2.55. Revenue jumped 19% year-over-year to $2.89 billion, also topping forecasts of roughly $2.8–$2.9 billion. Global procedures using the company's da Vinci and Ion robotic platforms rose about 16%, with Ion procedures surging 36% and da Vinci procedures climbing 15%.

Yet beneath those headline figures, a troubling pattern emerged in the company's largest market. US da Vinci procedure growth slowed to 12% in the second quarter, down from 14% in the first quarter. Management pointed to the expiration of enhanced subsidies under the Affordable Care Act as a likely culprit, saying some patients are postponing elective, non-urgent surgeries. The weakness in the US was compounded by a challenging bidding environment in China, raising questions about the sustainability of the high growth rates that investors had come to expect.

The real catalyst for the selloff, however, was the unchanged full-year guidance. Intuitive reiterated its 2026 procedural growth forecast of 13.5% to 15.5%, with management signaling that growth would likely land near the midpoint of that range — implying a significant deceleration in the second half. After a quarter that beat expectations across the board, the market had been anticipating an upward revision. The absence of one was taken as a tacit admission that the best days of this year are behind.

A separate overhang came from a Class II recall involving 454 components of the da Vinci system, linked to a brake-pin defect discovered earlier in 2026. While the recall is not unprecedented for a device manufacturer, it keeps investors focused on quality control and regulatory risk at a time when the company is already navigating margin pressure from tariffs and the ramp-up of the da Vinci 5 platform. Intuitive expects full-year adjusted gross margins of 68.0% to 69.0%, weighed down by those costs.

The stock now sits 41.53% below its 52-week high of €516.50, reached on January 7. The relative strength index has fallen to 29.9, deep in oversold territory. Several major institutions, including JPMorgan and Citi, have trimmed their price targets in response to the altered growth outlook and the ACA-related uncertainty. Still, a number of analysts maintain positive ratings, arguing that the long-term adoption story for robotic surgery remains intact.

Intuitive, meanwhile, continues to advance its pipeline. Several new systems are awaiting FDA clearance, including a flexible robotic endoscope, and the da Vinci 5 recently received regulatory approval in India. Whether those catalysts can rebuild investor confidence before the next quarterly report will be the central question for the second half of 2026.